Physician profile
Jolly Mathew
NPI 1881782985
$4,109.20
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $387 · 2021: $845 · 2022: $863 · 2023: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.47 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $854.16 | 2020-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $722.90 | 2019-2023 | Farxiga |
| Amgen INC. | $452.61 | 2019-2022 | |
| Vifor Pharma, INC. | $319.91 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $304.55 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $227.67 | 2019-2023 | Jynarque |
| Akebia Therapeutics INC | $196.56 | 2020-2023 | Auryxia |
| Glaxosmithkline, LLC. | $148.71 | 2021-2023 | Benlysta |
| Amarin Pharma, INC. | $145.03 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $136.02 | 2019-2023 | Velphoro, Korsuva |
| Ani Pharmaceuticals, INC. | $104.89 | 2023 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $93.73 | 2022-2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $73.56 | 2019 | |
| Horizon Therapeutics Plc | $62.20 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.44 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.67 | 2022 | |
| Lilly USA, LLC | $26.53 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $24.33 | 2022 | |
| Calliditas Therapeutics US INC. | $23.87 | 2023 | Tarpeyo |
| Novo Nordisk INC | $21.98 | 2023 | Rybelsus, Ozempic |
| Genzyme Corporation | $20.36 | 2019 | |
| Baxter Healthcare | $19.84 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.16 | 2019 | |
| Allergan, INC. | $13.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolly Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.